Thomas Smith

Thomas Smith

Analyst-Equity chez Leerink Partners LLC

Finance
Technology Services
Consumer Services

Profil

Mr. Thomas J.
Smith
is a Senior Managing Director of Immunology & Metabolism at Leerink Partners LLC.
He is also a Senior Research Analyst covering Immunology and Metabolism.
Prior to covering the Immunology and Metabolism sector, Mr. Smith was a key member of Leerink Partners’ Targeted Oncology team helping to deliver in-depth fundamental research to clients.
Prior to joining the firm in 2018, he was most recently a Vice President and Research Analyst at Morgan Stanley, covering leading and emerging biopharmaceutical companies across numerous therapeutic areas, including oncology, NASH, and lead coverage of women’s health companies.
Prior to that, he worked at FBR Capital Markets on the biotechnology team, responsible for coverage of large, mid-, and small cap companies.
Mr. Smith began his career at Bloomberg where he held roles of increasing responsibility, including coverage of the biotech and specialty pharmaceutical sectors for Bloomberg Intelligence.
He earned his B.S.
in Finance and Psychology from The College of New Jersey.

Postes actifs de Thomas Smith

SociétésPosteDébut
Analyst-Equity 01/05/2018
Tous les postes actifs de Thomas Smith

Anciens postes connus de Thomas Smith

SociétésPosteFin
Analyst-Equity 01/05/2018
Analyst-Equity 31/12/2014
Corporate Officer/Principal 30/04/2014
Corporate Officer/Principal 31/05/2007
Voir l'expérience en détail de Thomas Smith

Formation de Thomas Smith

The College of New Jersey Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Thomas Smith

Relations

99

Relations au 1er degré

6

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées5

Finance

Technology Services

Finance

Finance

Finance

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Thomas Smith
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT